Prognostic and predictive factors in high-grade gliomas. Experience at our institution

被引:0
|
作者
Alonso, Diana [1 ]
Matallanas, Manuel [1 ]
Riveros-Perez, Alba [2 ]
Perez-Payo, Maripaz [1 ]
Blanco, Sonia [1 ]
机构
[1] HUCA, Serv Oncol Radioterap, Oviedo, Spain
[2] Hosp Univ Doctor Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Las Palmas, Spain
来源
NEUROCIRUGIA | 2017年 / 28卷 / 06期
关键词
Glioma; Glioblastoma; Astrocytoma; GLIOBLASTOMA; MGMT; CLASSIFICATION; TEMOZOLOMIDE; METHYLATION; TUMORS;
D O I
10.1016/j.neucie.2017.07.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectiue: To describe and analyse predictive and prognostic factors of overall survival (OS) in high-grade gliomas at our institution. Material and method: All patients diagnosed with grade in (GIII) or grade iv (GIV) gliomas (excluding oligodendrogliomas, oligoastrocytomas or infratentorial gliomas) were prospectively included from November 2010 to August 2014. All were treated with surgery followed by adjuvant radiochemotherapy. The Kaplan-Meier method was used for the statistical analysis, considering a P value <.05 to be significant. Results: 89 patients were studied (18 GIII and 71 GIV). The average age was 60 years and 55% were men. The mean Karnofsky score was 80%. The most common location was the frontal lobe (38%). A total of 65% were partial resections. Complete chemotherapy was administered to 74% and complete RT to 83% of patients. Mean OS was 26.8 8.3 months for GIII and 12.5 1 month for GIV. 72 had died by the end of this study. A total of 40% of patients had MGMT methylation, 7% IDH1 mutation and 47% EGFR amplification. Statistically significant variables for OS were: GIII (P=.020), age <70 years (P=.040), <65 years (P=.013) and <60 years (P=.003), Kamofsky >70% (P=.029), complete radiotherapy (P=.000), complete resection (P=.001), MGMT methylation (P=.042), IDH1 mutation (P=.007) and EGFR non-amplification (P=.034). Additionally, GIII and GN subgroups were independently analysed. In GIII, the only significant biomarker for OS was IDH1 mutation, while in GN, MGMT methylation (P=.023) was significant. Age >70 years old was a significant factor in the GIII-subgroup (P=.040) but not for GIV (P=.166). Conclusions: Data are in line with previous studies, with the exception of age, which does not appear to be significant in GIV. 2017 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [1] The prognostic effect of hemoglobin levels on survival for patients with high-grade gliomas.
    Lally, BE
    Colasanto, JM
    Knisely, JPS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 123S - 123S
  • [2] Adults with newly diagnosed high-grade gliomas.
    Croteau D.
    Mikkelsen T.
    Current Treatment Options in Oncology, 2001, 2 (6) : 507 - 515
  • [3] The prognostic factors and nomogram for patients with high-grade gliomas
    Qu, Shanqiang
    Qiu, Ouwen
    Hu, Zhicheng
    FUNDAMENTAL RESEARCH, 2021, 1 (06): : 824 - 828
  • [4] SURVIVAL AND PROGNOSTIC FACTORS IN HIGH-GRADE BRAIN GLIOMAS
    Lopez Carrizosa, M. C.
    Boveda, E.
    Garcia, S.
    Julia, M.
    Nieto, A.
    Herruzo Cabrera, I.
    Sevillano, M. D. M.
    Marcos Jimenez, F. J.
    Garcia Alonso, E.
    Almendros, P.
    Samper Ots, P. M.
    Conde-Moreno, A. J.
    Rubio Jimenez, M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S273 - S273
  • [5] Prognostic factors in elderly patients with grade 3 gliomas.
    Satra, A.
    Hashemi-Sadraei, N.
    Bawa, H. S.
    Peereboom, D. M.
    Stevens, G.
    Rybicki, L. A.
    Suh, J. H.
    Vogelbaum, M. A.
    Weil, R.
    Barnett, G.
    Ahluwalia, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Prognostic model of lower grade gliomas.
    Aoki, Kosuke
    Suzuki, Hiromichi
    Nakamura, Hideo
    Motomura, Kazuya
    Mizoguchi, Masahiro
    Abe, Tatsuya
    Muragaki, Yoshihiro
    Wakabayashi, Toshihiko
    Ogawa, Seishi
    Natsume, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Prognostic significance of loss of chromosome 10 in high grade gliomas.
    Balesaria, S
    Brock, C
    Bower, M
    Lewis, P
    Newlands, ES
    Fisher, RA
    BRITISH JOURNAL OF CANCER, 1999, 80 : 30 - 30
  • [8] A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors
    Shi, Weiyan
    Wang, Xuanzhong
    Liu, Shiyu
    Zheng, Zhuangzhuang
    Dong, Lihua
    Jiang, Xin
    CANCER MEDICINE, 2024, 13 (15):
  • [9] MULTIDISCIPLINARY TREATMENT OF ADULT HIGH GRADE GLIOMAS. INSTITUTIONAL EXPERIENCE
    Gaspar, C.
    Lorca, J.
    Piquer, J.
    Lopez, M.
    Riesgo, P.
    Llacer, J. L.
    Soler, M.
    Monroy, J. L.
    Garcera, S.
    Cuevas, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 335 - 335
  • [10] RADIOCHEMOTHERAPY IN HIGH-GRADE GLIOMAS. IMPACT OF EXTENDING ADJUVANT CHEMOTHERAPY WITH TEMOZOLOMIDE
    Vinchon, Sandrine
    Jadaud, Eric
    Soulie, Patrick
    Menei, Philippe
    Michalak, Sophie
    Gamelin, Erick
    NEURO-ONCOLOGY, 2008, 10 (05) : 882 - 882